Sanofi (NASDAQ:SNY) Hits New 1-Year High – Time to Buy?

Sanofi (NASDAQ:SNY)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $59.12 and last traded at $59.12, with a volume of 2131990 shares trading hands. The stock had previously closed at $57.70.

Analyst Upgrades and Downgrades

SNY has been the subject of several analyst reports. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $60.00.

Sanofi Stock Down 0.3 %

The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The company has a fifty day moving average price of $52.44 and a 200 day moving average price of $52.73. The company has a market cap of $150.37 billion, a PE ratio of 23.80, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Hedge Funds Weigh In On Sanofi

A number of hedge funds and other institutional investors have recently modified their holdings of SNY. Synergy Asset Management LLC bought a new position in Sanofi during the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. grew its holdings in shares of Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the last quarter. Lee Danner & Bass Inc. purchased a new position in Sanofi in the 4th quarter worth $31,000. Bessemer Group Inc. boosted its position in Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock valued at $32,000 after buying an additional 242 shares during the period. Finally, Sunbelt Securities Inc. grew its stake in shares of Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after buying an additional 313 shares during the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.